论文部分内容阅读
腹腔内感染能够导致严重疾患甚至死亡,而氟喹诺酮类是临床上对付这类感染的常用药物。6项非随机前瞻性临床研究结果显示,用氟喹诺酮类药物治疗腹腔内感染的临床成功率为77%～94%。10项随机对照试验对氟喹诺酮与其他常用疗法(主要是β-内酰胺类)治疗腹内感染进行了研究,除在其中2项随机对照研究中氟喹诺酮组的临床成功率在统计学上明显高于对照组外,其余8项研究中2个治疗组的临床成功率、细菌清除率、死亡率以及因毒性而撤出研究的患者比例基本相当。总之,氟喹诺酮类是临床上对付腹内感染的一类有效而且相对安全的抗菌剂。
Intraperitoneal infection can lead to serious illness and even death, and fluoroquinolones are clinically used to deal with such infections commonly used drugs. Six non-randomized, prospective clinical studies showed that the clinical success rate of fluoroquinolones treatment of intraperitoneal infections ranged from 77% to 94%. Ten randomized controlled trials of fluoroquinolone and other commonly used therapies (mainly beta-lactams) for the management of intra-abdominal infections were performed, except in two of the randomized controlled trials, where the fluoroquinolone clinical success rates were statistically significant Higher than the control group, the remaining 8 studies in the two treatment groups clinical success rate, bacterial clearance, mortality and the proportion of patients withdrawn from the study because of toxicity. In conclusion, fluoroquinolones are clinically effective and relatively safe antibacterial agents against intra-abdominal infections.